Antibody-drug conjugates (ADCs) are fast becoming an established class of biopharmaceuticals with therapeutic applications in oncology and beyond. ADCs combine a monoclonal antibody conjugated to a highly potent cytotoxic payload via a suitable linker, that targets an antigen expressed in certain cancer cells. Using antibodies to target conjugated highly potent cytotoxic payloads to tumor cells has proven an effective means of increasing efficacy while reducing safety issues associated with systemic chemotherapeutic approaches.
The design of ADCs is complex with interconnected components requiring optimization in parallel during the early development stage. To successfully meet the criteria of the drug Target Product Profile (TPP) an understanding of the risks and liabilities early in the design and development stages of the ADC is critical and allows modifications in the design before entering the more expensive stages of drug development.
Considering ADC developability early in drug development will reduce failure rates by providing multiple readouts that capture the fundamental characteristics of successful drug design: specificity, functionality/potency, safety, pharmacokinetics and manufacturability. This rational design and cascade approach allows the evaluation of all the ADC components in combination – antibody, linker and payload.
The webinar highlights the importance of de-risking ADC candidates, to support the generation of data for lead candidate selection through an ADC developability approach. Join this webinar for an overview of how to construct a lead ADC candidate, how to develop and apply suitable analytical workflows to select the best ADC lead candidate and considerations and mitigation of risks for overall best in class bioconjugate design.
The expert speakers will discuss the different requirements for optimising the right combination of ADC components and how the analytical and biological testing at the different preclinical stages can be applied to select the right antibody, linker and payload combination, such as:
· How to select the right antibody for ADCs
· Building and selecting the ADC lead candidate
· Analytical characterisation and evaluation of the desired ADC candidate
Register for this webinar to learn more about the drug development applications of ADC developability and hear about case studies which illustrate the approaches used to overcome challenges in their design and testing.
Key Learning Objectives
- How to construct a lead ADC candidate
- Application of an analytical workflow to select the best ADC lead candidate
- Consideration and mitigation of risks in the overall best in class bioconjugate design
